Literature DB >> 30908865

H2 O2 -Responsive Organosilica-Doxorubicin Nanoparticles for Targeted Imaging and Killing of Cancer Cells Based on a Synthesized Silane-Borate Precursor.

Yanhui Xu1,2, Wen Shi1,2, Hongyu Li1, Xiaohua Li1, Huimin Ma1,2.   

Abstract

Doxorubicin (Dox) is a widely used fluorescent chemotherapy drug. Its primary delivery systems, based on physical adsorption to silica nanoparticles, can lead to low drug loading. Direct loading of Dox via covalent bonds during the formation of silica nanoparticles has never been reported. In this work, we designed and synthesized a silane-borate precursor, which contains not only an alkoxysilane moiety to form organosilica nanoparticles but also a phenylboronic acid moiety to react with diol-containing compounds. Using this compound, the covalent loading of Dox during the preparation of organosilica nanoparticles was effectively realized with a high drug loading content up to 22.4 %. Further modification by hyaluronic acid (HA) bestowed the Si-Dox@HA nanoparticles with the ability to target CD44-overexpressing cancer cells. The Si-Dox@HA nanoparticles exhibited H2 O2 -responsive release of about 80 % Dox and displayed seven-fold selectivity for killing cancer cells over normal cells, relative to Dox and Si-Dox nanoparticles. Moreover, these Si-Dox@HA nanoparticles are also suitable for targeted fluorescence imaging of CD44-overexpressing cancer cells.
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  H2O2-responsive chemotherapy; cytotoxicity; drug delivery; silanes; targeted imaging

Mesh:

Substances:

Year:  2019        PMID: 30908865     DOI: 10.1002/cmdc.201900142

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  1 in total

1.  A Fluorescent Activatable AND-Gate Chemokine CCL2 Enables In Vivo Detection of Metastasis-Associated Macrophages.

Authors:  Antonio Fernandez; Emily J Thompson; Jeffrey W Pollard; Takanori Kitamura; Marc Vendrell
Journal:  Angew Chem Int Ed Engl       Date:  2019-10-11       Impact factor: 15.336

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.